Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: A nested case-control study in UK primary care

Drug Safety

Volumn 34, Issue 11, 2011, Pages 1061-1077

  Martín Merino, Elisa ^a   Johansson, Saga ^b,c   Morris, Thomas ^d   García Rodríguez, Luis A ^a  

^a Spanish Centre for Pharmacoepidemiological Research ^*  (Spain)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Antiandrogens; Bicalutamide; Coronary disorders; Cyproterone; Flutamide; Heart failure; LHRH receptor agonists; Myocardial infarction; Prostate cancer

Indexed keywords

BICALUTAMIDE; CYPROTERONE; FLUTAMIDE; GONADORELIN ANTAGONIST;

ACUTE HEART INFARCTION; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORCHIECTOMY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY DISEASE; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 80053897293     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11594540-000000000-00000     Document Type: Article

References (37)

1. Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2006. Newport: The Office for National Statistics, 2008
2. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 2009 Apr; 10 (4): 351-69
3. Cancer Research UK. London. Prostate cancer: survival statistics [online]. Available from URL: http://info.cancer researchuk.org/cancerstats/ types/prostate/survival/[Accessed 2011 Sep 8]
4. American Cancer Society. Cancer facts & figures 2008. Atlanta (GA): American Cancer Society, 2008
5. Walsh PC. Physiologic basis for hormonal therapy in carci-noma of the prostate. Urol Clin North Am 1975 Feb; 2 (1): 125-40
6. Heidenreich A, Bolla M, Joniau S, et al. European Asso-ciation of Urology guidelines on prostate cancer: update January 2011 [online]. Available from URL: http://www. uroweb.org/gls/pdf/08-Prostate-Cancer%20July%206th.pdf [Accessed 2011 Sep 16]
7. Singer EA, Golijanin DJ, Miyamoto H, et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008 Feb; 9 (2): 211-28 (Pubitemid 351233730)
8. Yannucci J, Manola J, Garnick MB, et al. The effect of an-drogen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006 Aug; 176 (2): 520-5 (Pubitemid 43927931)
9. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006 Apr; 91 (4): 1305-8
10. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006 Feb 1; 106 (3): 581-8 (Pubitemid 43157621)
11. Braga-Basaria M, Muller DC, Carducci MA, et al. Lipo-protein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006 Sep-Oct; 18 (5): 494-8 (Pubitemid 44330303)
12. Bolla M, Van Tienhoven G, Warde P, et al. External irra-diation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010 Nov; 11 (11): 1066-73
13. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009 Jan 1; 27 (1): 92-9
14. Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol 2004 Nov; 172 (5 Pt 1): 1865-70 (Pubitemid 39363075)
15. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006 Feb; 97 (2): 247-54
16. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010 Jan 6; 102 (1): 39-46
17. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 Sep 20; 24 (27): 4448-56 (Pubitemid 46630983)
18. Saigal CS, Gore JL, Krupski TL, et al. Androgen depriva-tion therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 Oct 1; 110 (7): 1493-500 (Pubitemid 47463063)
19. D'Amico AV, Chen MH, Renshaw AA, et al. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 2008 Dec 15; 113 (12): 3290-7
20. D'Amico AV, Denham JW, Crook J, et al. Influence of an-drogen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007 Jun 10; 25 (17): 2420-5 (Pubitemid 46999213)
21. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen de-privation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007 Oct 17; 99 (20): 1516-24 (Pubitemid 351767235)
22. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 2010 Jul 20; 28 (21): 3448-56
23. Robinson D, Garmo H, Lindahl B, et al. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. Int J Cancer. Epub 2011 Mar 8
24. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009 Jul 20; 27 (21): 3452-8
25. GPRD. The GPRD practice and patient populations [online]. Available from URL: http://www.gprd.com/products/database.asp [Accessed 2011 Jun 13]
26. Lawson DH, Sherman V, Hollowell J. The general practice research database. Scientific and Ethical Advisory Group. Q J Med 1998 Jun; 91 (6): 445-52 (Pubitemid 28286844)
27. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010 Jan; 69 (1): 4-14
28. Ronquist G, Rodriguez LA, Ruigomez A, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004 Jan 1; 58 (1): 50-6 (Pubitemid 38057988)
29. García Rodríguez LA, Gonzalez-Perez A. Inverse associa-tion between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004 Apr; 13 (4): 649-53 (Pubitemid 38737903)
30. García Rodríguez LA, Varas-Lorenzo C, Maguire A, et al. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004 Jun 22; 109 (24): 3000-6 (Pubitemid 38808323)
31. García Rodríguez LA, Varas C, Patrono C. Differential ef-fects of aspirin and non-aspirin nonsteroidal antiin-flammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000 Jul; 11 (4): 382-7 (Pubitemid 30428929)
32. Jones TH. Testosterone deficiency: a risk factor for cardio-vascular disease? Trends Endocrinol Metab 2010 Aug; 21 (8): 496-503
33. Rahman F, Christian HC. Non-classical actions of testo-sterone: an update. Trends Endocrinol Metab 2007 Dec; 18 (10): 371-8
34. Tsang S, Liu J, Wong TM. Testosterone and cardioprotec-tion against myocardial ischemia. Cardiovasc Hematol Disord Drug Targets 2007 Jun; 7 (2): 119-25 (Pubitemid 47024127)
35. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association. Circulation 2010 Feb 16; 121 (6): 833-40
36. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005 Sep 24-30; 366 (9491): 1059-62 (Pubitemid 41338752)
37. Rothman KJ, Greenland S, Lash TL. Modern epidemiol-ogy. 3rd ed. Philadelphia (PA): Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008